{
  "chunk_id": "V_iii_9_None_20",
  "content": "/>\nV.iii.9.2.f\n.\nHistorical P&T Evaluations\nHistorical policy guidance in existence prior to the December 9, 2018, rating schedule update directed the assignment of P&T evaluations for CLL and multiple myeloma.  P&T evaluations assigned under the prior version of the rating schedule with application of those policies are protected under\n38 CFR 3.951(a)\n.\nP&T evaluations were directed\nfrom November 6, 2003, to December 9, 2018, for CLL, with diagnosis being the sole requirement unless the condition was considered cured via treatment with a bone marrow transplant, and\nfrom January 28, 2003, to December 9, 2018, for multiple myeloma unless an exceptional situation was present in which inactive multiple myeloma was documented.\nImportant\n:\nIn all situations, the evidence of record must be analyzed to determine the treatment plan and prognosis for active malignancy associated with CLL or multiple myeloma.  As directed in\nM21-1, Part V, Subpart ii, 3.D.4\n, assign a P&T evaluation for active malignancy when warranted, whether the disability is evaluated under historical or current rating criteria.\nRevisions to\n38 CFR 4.117, DCs 7703 and 7712\neffective on December 9, 2018, provide criteria for scheduling review examinations for CLL and multiple myeloma unless there is clear evidence establishing a terminal prognosis.",
  "title": "M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems",
  "citation": "Part V, Subpart iii, Chapter 9, Section None",
  "source_url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems",
  "updated": "",
  "scraped_at": "2025-06-16T22:45:35.239285",
  "tags": [
    "m21-1"
  ]
}